The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience

• Published in: Therapeutic advances in respiratory disease Vol. 10; no. 1; pp. 43 - 56
• Main Authors: Albertson, Timothy E., Richards, John R., Zeki, Amir A.
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.02.2016; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Administration, Inhalation; Androstadienes - administration & dosage; Androstadienes - adverse effects; Androstadienes - therapeutic use; Anti-Asthmatic Agents - administration & dosage; Anti-Asthmatic Agents - adverse effects; Anti-Asthmatic Agents - therapeutic use; Asthma; Asthma - drug therapy; Asthma - physiopathology; Benzyl Alcohols - administration & dosage; Benzyl Alcohols - adverse effects; Benzyl Alcohols - therapeutic use; Chlorobenzenes - administration & dosage; Chlorobenzenes - adverse effects; Chlorobenzenes - therapeutic use; Drug Combinations; Forced Expiratory Volume; Glucocorticoids - administration & dosage; Glucocorticoids - adverse effects; Glucocorticoids - therapeutic use; Humans; Inhalers; Respiratory therapy; Reviews; fluticasone furoate/vilanterol trifenatate; persistent asthma; powder inhaler; long-acting β2 agonist; combined inhaler; inhaled corticosteroid
• ISSN: 1753-4666; 1753-4658; 1753-4666
• DOI: 10.1177/1753465815619136

The treatment of persistent asthma has been aided by the recent approval of new medications. The combined inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) powder inhaler fluticasone furoate (FF)/vilanterol trifenatate (VI) is one of these new agents, which was recently approved as a maintenance therapy for persistent asthma. This once-daily ICS/LABA inhaler has previously been approved and used in chronic obstructive pulmonary disease as a maintenance therapy. Both FF and VI individually have been shown to have efficacy in the treatment of persistent asthma; the combination of FF/VI at the dose of 100/25 μg daily improves trough peak expiratory flows and forced expiratory volume in 1 s. It also reduces the frequency of asthma exacerbations in patients with persistent asthma. The once-daily dosing is well tolerated, with limited clinically significant adverse events; the once-daily inhaled dosing regimen should also improve medication adherence. The data supporting the use of the FF/VI inhaler in persistent asthma are reviewed. The dry powder inhaler of FF/VI (100/25 μg) is an effective and well tolerated once-daily maintenance treatment for patients with persistent asthma.